CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
Lamictal (lamotrigine) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00513019
NCT00513019Phase 2Completed
CompareCT.gov

A Double-Blind Study of Lamictal in Neurotic Excoriation

University of Chicago·interventional·Posted Aug 8, 2007·Updated Feb 23, 2023

In Brief

A Phase 2 clinical trial evaluating Lamictal (lamotrigine) and Placebo for Neurotic Excoriation and 3 related conditions. Completed, enrolled 35 participants across 1 site.

Detailed Summary

The goal of the proposed study is to evaluate the comparative efficacy of Lamictal (lamotrigine) to placebo in neurotic excoriation. Thirty subjects with neurotic excoriation will receive 12 weeks of double-blind treatment with Lamictal (lamotrigine) or matching placebo. The hypothesis to be tested is that Lamictal (lamotrigine) will be more effective than placebo in patients with neurotic excoriation. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurotic Excoriation, Pathologic Skin Picking, Psychogenic Excoriation, Dermatillomania
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 8, 2007
Enrollment StartAug 1, 2007
Primary CompletionAug 1, 2009
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.9 years ago

Interventions

Lamictal (lamotrigine)drug

once daily from beginning to end of study. Dosage varies.

Placebodrug

daily